Aclaris Therapeutics Stock Today
| ACRS Stock | USD 1.22 0.02 1.61% |
Performance0 of 100
| Odds Of DistressLess than 43
|
Aclaris Therapeutics is selling for under 1.22 as of the 23rd of April 2024; that is -1.61 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.21. Aclaris Therapeutics has about a 43 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Aclaris Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of June 2023 and ending today, the 23rd of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of October 2015 | Category Healthcare | Classification Health Care |
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Aclaris Therapts operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 70.92 M outstanding shares of which 4.89 M shares are presently shorted by private and institutional investors with about 4.06 trading days to cover. More on Aclaris Therapeutics
Follow Valuation Options Odds of Bankruptcy
Financial Report 13th of May 2024
Aclaris Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Aclaris Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Aclaris Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Neal Walker | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Aclaris Therapeutics report their recommendations after researching Aclaris Therapeutics' financial statements, talking to executives and customers, or listening in on Aclaris Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Aclaris Therapeutics. The Aclaris consensus assessment is calculated by taking the average forecast from all of the analysts covering Aclaris Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Aclaris Therapeutics' liquidity, profitability, solvency, and operating efficiency, Aclaris Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in May. Financial strength of Aclaris Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aclaris Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Aclaris Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aclaris Therapeutics' financial leverage. It provides some insight into what part of Aclaris Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aclaris Therapeutics (ACRS) is traded on NASDAQ Exchange in USA. It is located in 701 Lee Road, Wayne, PA, United States, 19087 and employs 86 people. Aclaris Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 87.95 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aclaris Therapeutics's market, we take the total number of its shares issued and multiply it by Aclaris Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Aclaris Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 70.92 M outstanding shares of which 4.89 M shares are presently shorted by private and institutional investors with about 4.06 trading days to cover.
Aclaris Therapeutics currently holds about 248.6 M in cash with (78.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Aclaris Therapeutics Probability Of Bankruptcy
Ownership AllocationAclaris Therapeutics holds a total of 70.92 Million outstanding shares. The majority of Aclaris Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aclaris Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aclaris Therapeutics. Please pay attention to any change in the institutional holdings of Aclaris Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Aclaris Ownership Details
Aclaris Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Aclaris Therapeutics jumping above the current price in 90 days from now is about 43.13%. The Aclaris Therapeutics probability density function shows the probability of Aclaris Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.9712. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Aclaris Therapeutics will likely underperform. Additionally, aclaris Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Aclaris Therapeutics to move above the current price in 90 days from now is about 43.13 (This Aclaris Therapeutics probability density function shows the probability of Aclaris Stock to fall within a particular range of prices over 90 days) .
Aclaris Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Aclaris Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aclaris Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aclaris Therapeutics' value.| Instituion | Recorded On | Shares | |
| Gsa Capital Partners Llp | 2023-12-31 | 1.6 M | |
| Two Sigma Investments Llc | 2023-12-31 | 1.5 M | |
| Two Sigma Advisers, Llc | 2023-12-31 | 1.4 M | |
| Geode Capital Management, Llc | 2023-12-31 | 1.4 M | |
| State Street Corporation | 2023-12-31 | 1.4 M | |
| Goldman Sachs Group Inc | 2023-12-31 | 1 M | |
| Vr Adviser, Llc | 2023-09-30 | 1 M | |
| Monaco Asset Management | 2023-12-31 | 979.4 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 975.9 K | |
| Bvf Inc | 2023-09-30 | 7.1 M | |
| Blackrock Inc | 2023-12-31 | 5.9 M |
Aclaris Therapeutics Historical Income Statement
Aclaris Therapeutics Income Statement is one of the three primary financial statements used for reporting Aclaris's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Aclaris Therapeutics revenue and expense. Aclaris Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Aclaris Therapeutics' Research Development is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 28.8 M in 2024, whereas Interest Expense is likely to drop slightly above 3.2 M in 2024. View More FundamentalsAclaris Stock Against Markets
Picking the right benchmark for Aclaris Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Aclaris Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Aclaris Therapeutics is critical whether you are bullish or bearish towards Aclaris Therapeutics at a given time. Please also check how Aclaris Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Aclaris Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Piotroski F Score Now
Piotroski F ScoreGet Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
| All Next | Launch Module |
Aclaris Therapeutics Corporate Directors
Aclaris Therapeutics corporate directors refer to members of an Aclaris Therapeutics board of directors. The board of directors generally takes responsibility for the Aclaris Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Aclaris Therapeutics' board members must vote for the resolution. The Aclaris Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| William Humphries | Director | Profile | |
| Andrew Powell | Independent Director | Profile | |
| Richard Bierly | Director | Profile | |
| Ketan Patel | Director | Profile |
How to buy Aclaris Stock?
Before investing in Aclaris Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Aclaris Therapeutics. To buy Aclaris Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Aclaris Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Aclaris Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Aclaris Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Aclaris Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Aclaris Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.
Already Invested in Aclaris Therapeutics?
The danger of trading Aclaris Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aclaris Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aclaris Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aclaris Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aclaris Therapeutics is a strong investment it is important to analyze Aclaris Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aclaris Therapeutics' future performance. For an informed investment choice regarding Aclaris Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Aclaris Stock analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Aclaris Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.448 | Quarterly Revenue Growth 1.266 | Return On Assets (0.33) | Return On Equity (0.50) |
The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.